Reports Q2 revenue $35,000, consensus $130,000. “With our pivotal Phase 3 study, Synpheny-3, now underway, we are focused on trial execution and ensuring access, inclusion and an optimal experience for the patients who participate in this landmark study of a potential breakthrough in the management of PKU,” said Aoife Brennan, M.B. Ch.B., Synlogic President and Chief Executive Officer. “We were also pleased to share important regulatory milestones for the product candidate this quarter, including receipt of the FDA’s Fast Track designation, reenforcing the great medical need for this investigational medicine, and the World Health Organization’s approval of the international non-proprietary name for SYNB1934: labafenogene marselecobac.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SYBX:
- Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update
- SYBX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Science 37, Synlogic partner on study for investigational drug phenylketonuria
- Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria
- Synlogic grants Fast Track designation from FDA for SYNB1934